Aura Biosciences 2025 net loss widens as R&D costs rise

Aura Biosciences

30/03/2026 12:09

Overview

US biotech's 2025 net loss widened as R&D expenses rose for late-stage clinical trials

General and administrative expenses declined, mainly due to reduced professional fees

Company expects cash reserves to fund operations into Q1 2027

Outlook

Aura expects to complete Phase 3 CoMpass enrollment by mid-2026, topline data in 2H 2027

Company expects initial 3-month NMIBC trial data in mid-2026

Aura says current cash and securities sufficient to fund operations into Q1 2027

Result Drivers

R&D SPENDING - Higher research and development expenses driven by ongoing clinical and CRO costs for Phase 3 trial of bel-sar in early choroidal melanoma and personnel growth

Company press release: ID:nGNX1nXFrK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$106.19 mln
FY Operating Expenses
$112.79 mln
FY Operating Income
-$112.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aura Biosciences Inc is $19.50, about 211% above its March 27 closing price of $6.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)